Cmero, M, Yuan, K, Ong, CS, Schrder, J, Adams, DJ, Anur, P, Beroukhim, R, Boutros, PC, Bowtell, DD, Campbell, PJ, Cao, S, Christie, EL, Cun, Y, Dawson, KJ, Demeulemeester, J, Eils, R, Fan, Y, Van Loo, P, Wang, W, Zhu, H, Akbani, R, Aldape, KD, Broaddus, R, Borresen-Dale, A, Chakravarty, D, Chen, K, Chen, Y, Czerniak, BA, El-Naggar, AK, Gershenwald, JE, Han, L, Huse, J, von Kalle, C, Krishnamurthy, S, Langerod, A, Lazar, A, Li, J, Liang, H, Lichter, P, Lu, Y, Mills, GB, Myklebost, O, Park, K, Plass, C, Sood, AK, Su, X, Thompson, A, Wang, L , Weinstein, JN, Yuan, Y
The Janus kinase inhibitor ruxolitinib (Opzelura) has been approved to treat nonsegmental vitiligo in adults and kids aged 12 or older
Over periods ranging from 1 to 4 years, no significant hepatotoxicity was observed, and incidences of ALT and AST elevations greater than three times the upper limit of normal (ULN) were rare
Although the progression of disease and the organ damage they cause is quite different, chronic fatigue is a lingering condition they all share
The safety of supplemental glutathione during these periods has not been extensively studied
The honest answer may be that you need pharmaceutical intervention, and there is nothing wrong with that decision
